Inhibikase Therapeutics (IKT) Operating Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Operating Expenses data on file, last reported at $17.8 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $17.8 million, up 22.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.2 million (up 43.78% YoY), and the FY2025 annual result was $52.0 million, up 81.8% from the prior year.
• Operating Expenses improved to $17.8 million in Q1 2026 per IKT's latest filing, from $13.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $17.8 million in Q1 2026 and troughed at $4.4 million in Q4 2022.
• A 5-year average of $8.1 million and a median of $5.1 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses declined 20.07% in 2024, then surged 205.25% in 2025.
• A 5-year view of Operating Expenses shows it stood at $4.4 million in 2022, then climbed by 0.11% to $4.4 million in 2023, then soared by 193.6% to $12.9 million in 2024, then increased by 6.55% to $13.8 million in 2025, then climbed by 29.52% to $17.8 million in 2026.
• Business Quant data shows IKT's Operating Expenses at $17.8 million in Q1 2026, $13.8 million in Q4 2025, and $12.8 million in Q3 2025.